A deal? An as­set sale? A launch? Every­one is watch­ing next moves for Roivant, Bridge­Bio

What’s next for two of biotech’s once-cool, now-hot com­pa­nies?

Hot on the heels of crit­i­cal da­ta read­outs, Roivant Sci­ences and Bridge­Bio Phar­ma are en­joy­ing two of 2023’s most dra­mat­ic stock turn­arounds, af­ter their briefly-out-of-fa­vor busi­ness mod­els have turned up po­ten­tial block­buster drugs.

Suc­cess­ful read­outs of the pro­grams — Roivant’s stom­ach drug, RVT-3101, and Bridge­Bio’s heart pill, aco­ramidis — have prompt­ed the sort of ques­tion that faces any small­er com­pa­ny af­ter pos­i­tive da­ta. In Roivant’s case, there have been re­ports that it plans to sell the drug for as much as $7 bil­lion — but no deal has ma­te­ri­al­ized. And Bridge­Bio was said to have at­tract­ed in­quiries from larg­er drug­mak­ers ahead of its read­out, but the com­pa­ny hasn’t an­nounced a deal or its own fi­nanc­ing plans.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER